Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20333945 | 0.83 | EPHX1 (0.49) | MAOBPPARAPPARGL3MBTL1 | |
| SCHEMBL20333729 | 0.83 | ITGB1 (0.40) | — | |
| SCHEMBL20350468 | 0.82 | TSHR (0.47) | PTPN1PPARAPPARG | |
| SCHEMBL20333376 | 0.81 | KMT2A (0.46) | SRD5A2L3MBTL1 | |
| SCHEMBL24835822 | 0.81 | MME (0.40) | FFAR1 | |
| SCHEMBL21602081 | 0.80 | PDCD1 (0.45) | FFAR1PPARAPPARG | |
| SCHEMBL20350670 | 0.80 | PPARA (0.43) | PTPN1SRD5A2MAOBPPARAPPARG | |
| SCHEMBL20350676 | 0.79 | FFAR1 (0.47) | FFAR1L3MBTL1 | |
| SCHEMBL24836153 | 0.79 | PARP10 (0.46) | MAOB | |
| SCHEMBL22216639 | 0.78 | RARB (0.46) | SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
| WO-2018119284-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | PTPN1 2175/4885SRD5A2 2460/4885MAOB 96/4885 |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | PTPN1 2175/4885SRD5A2 2460/4885MAOB 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.